SEATTLE, Sept. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTICD and MTA: CTIC) today announced that a single institutional investor shall purchase, for $14.2 million, newly issued 15.5% Convertible Senior Notes due 2012, with a conversion price of $1.27 per share. The transaction is the result of an amendment of a September 15, 2008 agreement (as amended on September 26, 2008) under which the investor had purchased $9 million of senior notes and given CTI an option to require the investor to purchase additional notes.
The new Notes would have a $14.2 million initial principal balance and feature a make-whole provision entitling the holder, upon any conversion of the Notes, to receive the interest payable through scheduled maturity, less any interest paid before conversion. The Company expects to receive net proceeds of approximately $5.4 million from the Notes (before payment of fees and expenses), after depositing amounts in escrow for the make-whole provision. The Notes will rank equal in right of payment with all existing and future unsecured senior indebtedness of the Company.
Pursuant to the agreement, CTI shall make a payment in the amount of $150,000 as an inducement for the investor and its affiliates to convert 1,000 shares of Series C Preferred Stock owned by the investor and its affiliates into Common Stock of the Company pursuant to the provisions of the Company's articles of incorporation. In connection with this securities transaction, CTI shall also make a payment to the investor and its affiliates in the amount of $1,225,000 in exchange for release of all pending claims against the Company, and shall enter into a mutual general release.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.
A prospectus supplement relating to the Convertible Notes to be issued in the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.
This press-release contains forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect future results. This announcement is neither an
offer to sell nor a solicitation of an offer to buy any of these securities
and shall not constitute an offer, solicitation or sale in any jurisdiction
in which such offer, solicitation or sale is unlawful. The Company
continues to have substantial amount of debt outstanding and the quarterly
interest expense associated with the debt is significant; the Company's
operating expenses continue to exceed its net revenues and the Company will
continue to need to raise capital to fund its operating expenses; as well
as other risks listed or described from time to time in the Company's most
recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required
by law, the Company does not intend to update any of the statements in this
press release upon further developments.
T : 206.272.4347
F : 206.272.4434
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved